



22nd October 2025

Vitasora Cornerstone Investor Placement Update

Highlights

- **AU\$2.43 million** in cash received from the cornerstone investor as part of their **AU\$6.75 million (USD \$4.5 million)** commitment at \$0.03 per share, with funds now cleared and available.
- A further **AU\$1.57 million due before 31 October 2025** and the remaining **AU\$2.75 million** committed to be received by 14 November 2025, progressing completion of the Company's AU\$11 million capital raise.
- Vitasora remains fully funded to achieve anticipated cash-flow breakeven by Q4 FY2026, supported by continued operational performance and strategic investment in technology, clinical operations, and business development.
- Strong execution momentum, including:
 - Expansion of the Tampa Family Medical Centers (TFMC) partnership to include Medicaid patients, substantially broadening program reach.
 - The Iris Healthcare collaboration, integrating Connected Care management into home and chronic-care models.
 - Multiple additional contracts in late-stage commercial discussions, highlighting sustained market confidence and a growing U.S. pipeline.
- Continued support from existing and new institutional investors reflects confidence in Vitasora's execution track record and leadership in Connected Care innovation.

Vitasora Health Limited (ASX: VHL; OTCQB: VHLUF) ("Vitasora" or "the Company") is pleased to confirm that it has received AU\$2.43 million in cleared funds as part of the cornerstone investor's AU\$6.75 million (USD \$4.5 million) commitment at \$0.03 per share, announced in July 2025.

A further AU\$1.57 million is due before 31 October 2025, with the final AU\$2.75 million committed to be received by 14 November 2025. Upon completion, the full cornerstone investment will total AU\$6.75 million, finalising the AU\$11 million capital raise that attracted strong participation from new institutional and strategic investors.

This funding milestone further strengthens Vitasora's balance sheet and ensures the Company remains fully funded to deliver on its operational growth plan and achieve forecast cash-flow breakeven by Q4 FY2026.

Fully paid ordinary shares (**Shares**) for the Cornerstone will be issued in two tranches, with the first allotment to be processed next week and the second one upon completion.

Vitasora CEO, Marjan Mikel, said: *"We're delighted to confirm that AU\$2.5 million from our cornerstone investor has now been received and banked, with the remaining funds contractually committed over the next few weeks. This outcome is especially important for our shareholders, who have been waiting for confirmation of this key funding milestone."*

"Our operational momentum continues to build, with the expanded Tampa Family Medical Centers program, the Iris Healthcare contract and several new partnerships in late-stage negotiation; all underscoring the strength of our Connected Care service and our execution capability which we are confident will see us achieve profitability in Q4, FY2026."



Strong Operational Momentum

The receipt of funds follows continued progress across Vitasora's U.S. operations:

- Tampa Family Medical Centers (TFMC) program now expanded to a 45,000-patient population, including Medicaid patients, under a fee-for-service model.
- The Iris Healthcare collaboration advancing chronic-care coordination for 12,000+ patients, further integrating Vitasora's Connected Care clinical oversight.
- Multiple additional partnerships in advanced negotiation stages, reflecting growing confidence from existing and new healthcare providers and payors in Vitasora's scalable model.

These initiatives, supported by recent investments in clinical and technology infrastructure, are driving revenue growth, operational efficiency, and margin improvement, positioning the Company to deliver sustained profitability and value creation.

Investor Outlook

With cash now received and the remaining cornerstone funds committed for completion by mid-November 2025, Vitasora is well-capitalised and operationally positioned to accelerate its U.S. growth strategy.

Management remains focused on disciplined execution and leveraging its proven Connected Care model to deliver sustainable growth, profitability, and long-term shareholder value.

For further information, investors and media please contact:

Mr Marjan Mikel

CEO & Managing Director
Vitasora Health Limited
P: +61 408 462 873
E: marjan@vitasorahealth.com

Mr Nicholas Smedley

Non-Executive Chairman
Vitasora Health Limited
P: +61 447 074 160
E: nicholas@vitasorahealth.com

This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:VHLUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.vitasorahealth.com.au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiTM app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respi.co/us/> or for [wheezo®](https://respi.co/us/)



Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.
wheezo® is a registered trademark of Vitasora Health Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora's current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.